The agency previously had a section on its website detailing how some U.S. healthcare providers have used hydroxychloroquine for COVID-19 patients and how the drug was “reportedly well-tolerated.”
The website also previously said the two drugs are “currently recommended for treatment of hospitalized COVID-19 patients in several countries.”
The section on hydroxychloroquine and chloroquine now is only one paragraph explaining that the drugs are “under investigation in clinical trials,” according to Talking Points Memo.
Reuters previously reported that the section on the two drugs appeared on the CDC website shortly after President Donald Trump touted the benefits of the drugs against COVID-19, though neither of the drugs has been proven to be effective against the disease.
Becker’s Hospital Review has reached out to the CDC for comment and will update this story accordingly.
Read the full article here.
More articles on pharmacy:
Johnson & Johnson warns of temporary Tylenol shortage
A breakdown of 6 of the most promising COVID-19 treatments
Employees test positive for COVID-19 at mail-order VA pharmacy in South Carolina
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
